Table 1.

Some advanced theranostic nanomedicine platforms under progress for simultaneous integration of diagnosis and therapy.

Type of theranostic nanomedicine	Material (s)	Therapeutic agent	Diagnostic agent	Size	Targeting agent	Advancement	Reference
Drug-polymer conjugates	HPMA	64Cu	64Cu	N.A.	RGD	Cancer imaging and radiochemo-therapy	39
Polymeric nanoparticles	PLA-TPGS	Docetaxel	Quantum dots	~ 250nm	Folic acid	Co-delivery of docetaxel and quantum dots	59
Solid lipid nanoparticles	Low-density lipoprotein, Cholesterol	Paclitaxel/ siRNA	Quantum dots	~ 130nm	cRGD	Multimodal therapy	66
Dendrimers	Polypropyleni-mine	Phthalocyanines	Phthalo cyanines	~ 62nm	LHRH	Delivery of single theranostic agent	75
Liposomes	TPGS, Phospholipids, Cholesterol	Docetaxel	Quantum dots	~ 210nm	Folic acid	Co-delivery of docetaxel and quantum dots	88
Micelles	TPGS	Iron oxide nanoparticles	Iron oxide nanoparticles	~ 178nm	Passive	Delivery of single theranostic agent	108
Gold nanoparticles	Gold nanoparticles	DOX	Gold nanoparticles	~ 55nm	CPLGLAGG peptide	Stimulus responsive drug release	120
Carbon nanomaterials	SWCNTs	Intrinsic property	Intrinsic property	Length of ~ 140nm	Passive	Self photolumines-cent and photothermal property	131